Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9513202 | 1.00 | TAAR1 (0.68) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL10872752 | 0.87 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL10872755 | 0.87 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL9651928 | 0.82 | TAAR1 (0.63) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL125442 | 0.81 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL256809 | 0.81 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL125440 | 0.81 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL2141223 | 0.80 | PNMT (0.60) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL5259036 | 0.80 | PNMT (0.60) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL2141228 | 0.80 | PNMT (0.60) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115948936-B | Extraction paper, preparation method thereof and application of extraction paper in amphetamine drugs detection | 中科检测技术服务(广州)股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| CN-118443818-A | Silanized polydopamine modified membrane, preparation method thereof and application thereof in amphetamine drugs and metabolite detection | 华南理工大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-115948936-B | Extraction paper, preparation method thereof and application of extraction paper in amphetamine drugs detection | 中科检测技术服务(广州)股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115948936-A | Extraction paper, preparation method thereof and application of extraction paper in detection of amphetamine drugs | 中科检测技术服务(广州)股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115855906-A | Method for detecting amphetamine in drugs based on anthracene-based probe | 中国科学院新疆理化技术研究所 | 2023-03-28 | — | — | CN | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| CN-202471713-U | Methyl-amphetamine reagent strip | HANGZHOU CLONGENE BIOTECH CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-5086181-A | Promoter for animal feeds; animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| US-4988694-A | Promoters for animal growth regulators for animal feeds | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4960783-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0339345-A2 | 4-Bromo-6-chloro-5-amino-2-pyridyl-ethanol amines, process for their preparation and their use as performance stimulators | BAYER AG (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0325802-A1 | Use of benzimidazole derivatives as operating capacity promotors | BAYER AG (DE) | 1989-08-02 | — | — | EP | disclosed |
| EP-0325131-A2 | Pyrimidine derivatives as performance stimulating agents | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4845262-A | NITRILE CONTAINING | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| EP-0259750-A2 | Aryl ethanol amines, process for their preparation and their use as growth promotors | BAYER AG (DE) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | TAAR1 4174/4885SLC6A2 3436/4885SLC6A3 3411/4885 |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | TAAR1 2835/4885SLC6A2 2558/4885SLC6A3 3180/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | TAAR1 4189/4885SLC6A2 3422/4885SLC6A3 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.